Yonsei Med J.  1990 Dec;31(4):367-374. 10.3349/ymj.1990.31.4.367.

Postoperative radiotherapy for stage IB carcinoma of the uterine cervix

• Seong J
• Loh JJ
• Kim G
• Suh C
• Kim J
• Park T

• KMID: 1729584
• DOI: http://doi.org/10.3349/ymj.1990.31.4.367

Abstract

Sixty patients, treated with postoperative radiation therapy following radical hysterectomy and pelvic lymphadenectomy for stage lb carcinoma of the uterine cervix between Jan. 1980 and Dec. 1984 at Department of Radiation Oncology, Yonsei University College of Medicine, were retrospectively analysed. The minimum follow-up period was 5 years. The indications for postoperative radiotherapy were positive pelvic lymph node (34 pts), a large tumor size more than 3 cm in longest diameter (18 pts), positive surgical margin (10 pts), deep stromal invasion (10 pts), and lymphatic permeation (9 pts). The overall 5-year survival rate was 81.8%. The univariate analysis of prognostic factors disclosed tumor size (less than 3cm, greater than or equal to 3cm) and the status of the surgical margin (positive, negative) as significant factors (tumor size; 88.1% vs 6.3%, surgical margin; 85.5% vs 60%, p less than 0.05). Age (less than or equal to 40, greater than 40 yrs) was marginally significant (90.2% vs 73.1%, p less than 0.1). Multivariate analysis clarified two independent prognostic factors; tumor size (p = 0.010) and surgical margin (p = 0.004). Analysis of the tumor factors with the radiation dose disclosed a better survival rate for patients with a positive surgical margin who were given over 50 Gy than for those who were given below 50 Gy in patients (4/4, 100% vs 2/6, 33.4%; p = 0.06). Significant complications requiring surgical correction were not observed. In conclusion, it is believed that the status of the surgical margin and tumor size both have important prognostic significance, and that a radiation dose over 50 Gy is advisable for patients with a positive surgical margin.

Keyword

Postoperative radiotherapy; stage Ib cervical carcinoima; survival; prognostic factor

MeSH Terms

Adult
Carcinoma/mortality/*radiotherapy/surgery
Cervix Neoplasms/mortality/*radiotherapy/surgery
Combined Modality Therapy
Female
Human
Hysterectomy
Lymph Node Excision
Lymphatic Metastasis
Prognosis
Retrospective Studies
Support, Non-U.S. Gov't